Amorfix sets up vCJD blood screening assay in UK and begins to test blood donor samples

    TSX: AMF

    TORONTO, Sept. 23 /CNW/ - Amorfix Life Sciences, a company focused on
treatments and diagnostics for brain wasting diseases, announced today it has
set up the EP-vCJD(TM) assay system in the Prion Laboratory at the British
National Institute for Biological Standards and Control (NIBSC) and has begun
to test fresh human blood samples as part of the ongoing assay validation
process announced earlier this year.
    "NIBSC and the UK National Blood Service have been exceedingly helpful in
establishing the performance of the EP-vCJD(TM) assay on routine samples from
blood donors," said Dr. George Adams, Chief Executive Officer of Amorfix. "We
expect to finish this alpha-site testing program in a month and demonstrate
the required specificity for the assay."
    Experts in the UK believe people may be infected for decades before
showing signs of vCJD. The number of people who contracted the disease by
consuming BSE-positive products is unknown. To date, four people have been
reported to have been infected through blood transfusion from donors who later
developed symptoms and died from vCJD. Blood transfusion services in low-risk
countries refuse to take blood from people who have lived in or visited
high-risk countries, where BSE-positive cattle were prevalent, to slow the
potential spread of the disease. A screening test for vCJD would allow more
people to be blood donors and increase the safety of the blood transfusion
services worldwide.

    About Amorfix

    Amorfix Life Sciences Ltd. (TSX:AMF) is a theranostics company developing
therapeutic products and diagnostic devices targeting brain-wasting diseases
including ALS, Alzheimer's Disease, Parkinson's Disease and variant
Creutzfeldt-Jakob Disease (vCJD). Amorfix's proprietary Epitope Protection(TM)
(EP) technology enables it to specifically identify very low levels of
aggregated misfolded proteins (AMP) in a sample of normal protein. Aggregated
misfolded proteins are a common element of many brain wasting diseases and the
ability to identify AMPs and understand their structure and mechanism of
folding are the first steps to developing new treatments for these devastating
diseases. Amorfix's lead programs are a diagnostic blood screening test for
vCJD and a therapy for ALS.

    This information release may contain certain forward-looking information.
Such information involves known and unknown risks, uncertainties and other
factors that may cause actual results, performance or achievements to be
materially different from those implied by statements herein, and therefore
these statements should not be read as guarantees of future performance or
results. All forward-looking statements are based on the Company's current
beliefs as well as assumptions made by and information currently available to
it as well as other factors. Readers are cautioned not to place undue reliance
on these forward-looking statements, which speak only as of the date of this
press release. Due to risks and uncertainties, including the risks and
uncertainties identified by the Company in its public securities filings,
actual events may differ materially from current expectations. The Company
disclaims any intention or obligation to update or revise any forward-looking
statements, whether as a result of new information, future events or

    %SEDAR: 00022789E

For further information:

For further information: Dr. George Adams, President & Chief Executive
Officer, Amorfix Life Sciences Ltd., Tel: (416) 847-6959, Fax: (416) 847-6899,; James Parsons, Chief Financial Officer, Amorfix Life
Sciences Ltd., Tel: (416) 847-6929, Fax: (416) 847-6899,

Organization Profile

Amorfix Life Sciences Ltd.

More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890